The prognostic value of FDG-PET scan in neuroendocrine tumors: a retrospective analysis of 46 patients treated in one center Abstract #90

Introduction: Neuroendocrine tumors (NETs) are rare and generally indolent. For diagnostic purposes, the sensitivity of FDG-PET scan is known to be low in this setting, though when positive, its prognostic value is not well-defined in NET.
Aim(s): To assess the value of FDG-PET on the prognosis of patients diagnosed with neuroendocrine tumors treated and followed-up in one center (Cliniques universitaires Saint-Luc, Brussels, Belgium).
Materials and methods: A retrospective analysis of all NET patients that benefited from an FDG-PET scan and Octreoscan® during their diagnostic work-up was made. Data regarding origin of the tumor, pathology characteristics (Ki-67 proliferation index) were analyzed according to FDG-PET positive or negative status. From 1999 until 12/2009, 46 patients (30 males), 55±15 years, had one FDG-PET scan; 43/46 also had an Octreoscan®. They consisted of 26 pancreatic tumors, nine midgut tumors, two duodenum, two main biliary tract, one lung, one stomach, one liver and three unknown primary NET. We looked at overall survival (OS) and time-to-therapeutic failure (TTF), which we defined as radiologic progression leading to a change in therapy. Survival and TTF curves were estimated according to the Kaplan-Meier method and compared with the Log-Rank test. A p-value <0.05 was considered significant.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Ivan Borbath

To read results and conclusion, please login ...

Further abstracts you may be interested in

#240 Glycodelin Expression in Pancreatic Neuroendocrine and Solid-Pseudopapillary Tumors as in Important Factor of Favorable Disease Prognosis
Introduction: Glycodelin (GD) is a multifunctional highly glycosylated protein, expressed in hormone-dependent human tissues and tumors. GD participates in apoptosis regulation and inter-cellular adhesion.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Larissa Gurevich
#311 Treatment and Prognosis of Patients with Poorly Differentiated Neuroendocrine Tumors
Introduction: Poorly differentiated neuroendocrine tumors (PDEC) represent less than 10% of all neuroendocrine tumors but have a poor prognosis.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Henning Grønbæk
#806 Long-Term Prognosis of Pancreatic Neuroendocrine Tumors in Von Hippel-Lindau Disease
Introduction: Management of pancreatic neuroendocrine tumours (PNET) associated with von Hippel-Lindau (VHL) disease is challenging because of their malignant potential and poorly predictable prognosis.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Louis De Mestier
#1282 Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Frequency, Treatment and Prognosis
Introduction: Data on peritoneal metastases (PM) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are scarce.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Ariana Madani
#2059 Finding the Options of Good Prognosis for Ampullary Neuroendocrine Tumors
Introduction: Ampullary neuroendocrine tumors are very rare. They account less than 1% of neuroendocrine gastrointestinal tumor. It is often difficult to establish a final diagnosis because of their resemblance with other adenocarcinomas of this origin.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zaidi S S A, ...